SCHEMBL4759002

SCHEMBL4759002

CC(C)(C(=O)N1CCC2(CC1)Cc1ccccc1C2)c1ccc(Cl)cc1

nearest known ligand 0.53

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 7/20 0.53
FNTA P49354 5/20 0.48
FNTB P49356 5/20 0.48
CNR1 P21554 1/20 0.46
HRH3 Q9Y5N1 1/20 0.42
MC4R P32245 1/20 0.41
CYP3A4 P08684 1/20 0.41
ALDH1A1 P00352 3/20 0.37
HTT P42858 1/20 0.37
MAPK1 P28482 1/20 0.37
CYP2C19 P33261 1/20 0.37
KDM4E B2RXH2 1/20 0.36
LMNA P02545 1/20 0.36
TSHR P16473 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
HSD17B10 Q99714 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4703361 0.80 HSD11B1 (0.50) HSD11B1FNTAFNTBCNR1MC4R
SCHEMBL4789139 0.76 KMT2A (0.56) ALDH1A1HTTMAPK1KDM4ELMNA
SCHEMBL4701904 0.76 HSD11B1 (0.48) HSD11B1CNR1ALDH1A1HTTLMNA
SCHEMBL4705538 0.76 PSEN1 (0.44) HSD11B1FNTAFNTBCNR1MC4R
SCHEMBL350217 0.74 HSD11B1 (0.65) HSD11B1ALDH1A1
SCHEMBL4756680 0.73 HRH3 (0.43) HSD11B1HRH3CYP3A4ALDH1A1MAPK1
SCHEMBL5361865 0.72 HSD11B1 (0.42) HSD11B1FNTAFNTBCNR1MC4R
SCHEMBL4759099 0.72 ALDH1A1 (0.47) HSD11B1HRH3ALDH1A1HTTMAPK1
SCHEMBL23902054 0.71 MAPK1 (0.51) HRH3CYP3A4MAPK1CYP2C19TSHR
SCHEMBL29609790 0.71 MAPK1 (0.51) HRH3CYP3A4MAPK1CYP2C19TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060009471-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2006-01-12 US claimed
EP-1758582-A4 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORP (US) 2008-01-09 EP disclosed
EP-1758582-A1 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS Incyte Corporation (US) 2007-03-07 EP disclosed
US-20060009471-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2006-01-12 US disclosed
WO-2006002349-A1 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORPORATION (US) 2006-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060009471-A1 Amido compounds and their use as pharmaceuticals HSD11B1, CYP11B1, HSD11B2 HSD11B1 1/4885FNTA 1066/4885FNTB 1034/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.